{"id":40042,"date":"2025-08-26T10:54:52","date_gmt":"2025-08-26T02:54:52","guid":{"rendered":"https:\/\/flcube.com\/?p=40042"},"modified":"2025-08-26T10:54:54","modified_gmt":"2025-08-26T02:54:54","slug":"beone-secures-950-m-deal-with-royalty-pharma-for-tarlatamab-rights","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40042","title":{"rendered":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights"},"content":{"rendered":"\n<p>On August\u202f26,\u202f2025, BeOne Medicines Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced that it had entered into an agreement with Royalty \u202fPharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/RPRX:NASDAQ\">NASDAQ:\u202fRPRX<\/a>) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.<\/p>\n\n\n\n<p><strong>Transaction Details<\/strong><br>Under the terms of the agreement, BeOne will receive an upfront payment of $885\u202fmillion and has the right to sell the remaining royalty rights for up to an additional $65\u202fmillion within 12\u202fmonths. BeOne will also retain the right to receive a percentage of the annual net sales of the product that exceeds $1.5\u202fbillion, based on the royalty proportion. Pursuant to its existing collaboration agreement with Amgen, BeOne will retain its royalty rights and all other rights to other products, including xaluritamig, a first\u2011in\u2011class, STEAP1 and CD3\u2011targeting XmAb bispecific antibody currently being studied in patients with metastatic castration\u2011resistant prostate cancer.<\/p>\n\n\n\n<p><strong>Product Overview<\/strong><br>Tarlatamab is a first\u2011in\u2011class immunotherapy that targets DLL3 protein on tumor cells and CD3 protein on T\u2011cells to activate T\u2011cells to kill DLL3\u2011expressing tumor cells. The drug has been approved in the U.S. for the treatment of adult patients with extensive\u2011stage small cell lung cancer (ES\u2011SCLC) with disease progression on or after platinum\u2011based chemotherapy.<\/p>\n\n\n\n<p><strong>Strategic Implications<\/strong><br>The deal provides BeOne with a substantial liquidity boost and a clear path to monetise its royalty stream from a high\u2011profile oncology asset. For Royalty\u202fPharma, the acquisition adds a proven, blockbuster\u2011qualified product to its portfolio, strengthening its position in the oncology royalty market. The transaction also reinforces the partnership with Amgen, ensuring that both companies can focus on developing and commercialising the broader pipeline of innovative therapies.<\/p>\n\n\n\n<p><strong>Conclusion<\/strong><br>By securing a $950\u202fmillion transaction for tarlatamab rights, BeOne is positioning itself to accelerate growth and deepen its engagement in the oncology space, while Royalty\u202fPharma expands its reach into high\u2011impact therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[330,2092,847,3046,4309,25,4308,848,2790],"class_list":["post-40042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-amgen","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-onc","tag-nasdaq-rprx","tag-potential-first-in-class","tag-royalty-pharma","tag-sha-688235","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40042\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights\" \/>\n<meta property=\"og:description\" content=\"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40042\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T02:54:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T02:54:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights\",\"datePublished\":\"2025-08-26T02:54:52+00:00\",\"dateModified\":\"2025-08-26T02:54:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2601.webp\",\"keywords\":[\"Amgen\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: ONC\",\"NASDAQ:\u202fRPRX\",\"Potential first-in-class\",\"Royalty Pharma\",\"SHA: 688235\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40042#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40042\",\"name\":\"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2601.webp\",\"datePublished\":\"2025-08-26T02:54:52+00:00\",\"dateModified\":\"2025-08-26T02:54:54+00:00\",\"description\":\"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40042\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40042#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights - Insight, China&#039;s Pharmaceutical Industry","description":"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40042","og_locale":"en_US","og_type":"article","og_title":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights","og_description":"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.","og_url":"https:\/\/flcube.com\/?p=40042","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T02:54:52+00:00","article_modified_time":"2025-08-26T02:54:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40042#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40042"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights","datePublished":"2025-08-26T02:54:52+00:00","dateModified":"2025-08-26T02:54:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40042"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","keywords":["Amgen","BeOne Medicines","HKG: 6160","NASDAQ: ONC","NASDAQ:\u202fRPRX","Potential first-in-class","Royalty Pharma","SHA: 688235","T cell engager"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40042#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40042","url":"https:\/\/flcube.com\/?p=40042","name":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40042#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","datePublished":"2025-08-26T02:54:52+00:00","dateModified":"2025-08-26T02:54:54+00:00","description":"On August\u202f26,\u202f2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had entered into an agreement with Royalty \u202fPharma (NASDAQ:\u202fRPRX) to sell its rights to royalties on worldwide net sales of tarlatamab (IMDELLTRA), a product licensed by Amgen, outside of China. The transaction is valued at up to\u202f$950\u202fmillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40042#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40042"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40042#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","width":1080,"height":608,"caption":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40042#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Secures $950\u202fM Deal with Royalty\u202fPharma for Tarlatamab Rights"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40042"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40042\/revisions"}],"predecessor-version":[{"id":40047,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40042\/revisions\/40047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40045"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}